Header Logo

Connection

WOLFGANG WINKELMAYER to Hemoglobins

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Hemoglobins.
WOLFGANG WINKELMAYER
Connection Strength
1.150
Hemoglobins
  1. The challenges of cost-effectiveness analyses for the clinician. Am J Kidney Dis. 2010 Dec; 56(6):1023-5.
    View in: PubMed
    Score: 0.325
  2. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol. 2012 Sep; 78(3):181-8.
    View in: PubMed
    Score: 0.092
  3. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011 Jan; 22(1):1-2.
    View in: PubMed
    Score: 0.082
  4. Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. Semin Dial. 2010 Sep-Oct; 23(5):486-91.
    View in: PubMed
    Score: 0.080
  5. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf. 2009 Oct; 18(10):932-40.
    View in: PubMed
    Score: 0.075
  6. Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant. 2004 Dec; 4(12):2075-81.
    View in: PubMed
    Score: 0.054
  7. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
    View in: PubMed
    Score: 0.049
  8. Market Competition and Anemia Management in the United States Following Dialysis Payment Reform. Med Care. 2023 Nov 01; 61(11):787-795.
    View in: PubMed
    Score: 0.049
  9. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003 Jul; 64(1):295-304.
    View in: PubMed
    Score: 0.049
  10. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
    View in: PubMed
    Score: 0.047
  11. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
    View in: PubMed
    Score: 0.046
  12. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
    View in: PubMed
    Score: 0.043
  13. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
    View in: PubMed
    Score: 0.042
  14. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
    View in: PubMed
    Score: 0.042
  15. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019 Jun; 22(6):593-604.
    View in: PubMed
    Score: 0.036
  16. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med. 2013 Jun; 126(6):541.e1-541.e14.
    View in: PubMed
    Score: 0.024
  17. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol. 2007 Aug; 22(8):1189-93.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.